References
1. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg . Aug 2001;10(3):146-52. doi:10.1053/spsu.2001.24695
2. Meza JL, Anderson J, Pappo AS, Meyer WH, Children’s Oncology G. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol . Aug 20 2006;24(24):3844-51. doi:10.1200/JCO.2005.05.3801
3. Dang ND, Dang PT, Samuelian J, Paulino AC. Lymph node management in patients with paratesticular rhabdomyosarcoma: a population-based analysis. Cancer . Sep 1 2013;119(17):3228-33. doi:10.1002/cncr.28198
4. Ecker BL, Peters MG, McMillan MT, et al. Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.Ann Surg Oncol . Feb 2017;24(2):425-433. doi:10.1245/s10434-016-5641-1
5. Lobeck I, Dupree P, Karns R, Rodeberg D, von Allmen D, Dasgupta R. Quality assessment of lymph node sampling in rhabdomyosarcoma: A surveillance, epidemiology, and end results (SEER) program study.J Pediatr Surg . Apr 2017;52(4):614-617. doi:10.1016/j.jpedsurg.2016.08.024
6. Hamilton EC, Miller CC, 3rd, Joseph M, Huh WW, Hayes-Jordan AA, Austin MT. Retroperitoneal lymph node staging in paratesticular rhabdomyosarcoma-are we meeting expectations? J Surg Res . Apr 2018;224:44-49. doi:10.1016/j.jss.2017.11.051
7. Brady AC, Picado O, Tashiro J, Sola JE, Perez EA. Lymph Node Sampling and Survival in Child and Adolescent Extremity Soft-Tissue Sarcoma.J Surg Res . Sep 2019;241:205-214. doi:10.1016/j.jss.2019.03.030
8. Routh JC, Dasgupta R, Chi YY, et al. Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer . Dec 1 2020;147(11):3168-3176. doi:10.1002/ijc.33143
9. Maduekwe UN, Herb JN, Esther RJ, Kim HJ, Spanheimer PM. Pathologic nodal staging for clinically node negative soft tissue sarcoma of the extremities. J Surg Oncol . May 2021;123(8):1792-1800. doi:10.1002/jso.26465
10. Liu QK, Yu XJ, Wang YG, et al. Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection. J Orthop Surg Res . Mar 18 2022;17(1):167. doi:10.1186/s13018-022-03050-3
11. Abdelazim YA, Zaki MF, Abdel Mohsen MM, et al. Treatment results of Para-Testicular Rhabdomyosarcoma (PT-RMS) using radiation as an alternative to retro-peritoneal nodal dissection: A single Institution experience. Arch Ital Urol Androl . Nov 15 2023;95(4):11642. doi:10.4081/aiua.2023.11642
12. Wharam MD, Meza J, Anderson J, et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol . May 15 2004;22(10):1902-8. doi:10.1200/JCO.2004.08.124
13. Lawrence W, Jr., Hays DM, Heyn R, et al. Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer . Aug 15 1987;60(4):910-5. doi:10.1002/1097-0142(19870815)60:4<910::aid-cncr2820600433>3.0.co;2-8
14. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol . Mar 1995;13(3):610-30. doi:10.1200/JCO.1995.13.3.610
15. Hibbitts E, Chi YY, Hawkins DS, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children’s Oncology Group. Cancer Med . Oct 2019;8(14):6437-6448. doi:10.1002/cam4.2504
16. Harrison DJ, Qumseya A, Xue W, et al. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer . Apr 2024;71(4):e30847. doi:10.1002/pbc.30847
17. Smith LM, Anderson JR, Qualman SJ, et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children’s oncology group. J Clin Oncol . Oct 15 2001;19(20):4058-64. doi:10.1200/JCO.2001.19.20.4058
18. Blatt J, Snyderman C, Wollman MR, et al. Delayed resection in the management of non-orbital rhabdomyosarcoma of the head and neck in childhood. Med Pediatr Oncol . Apr 1997;28(4):294-8. doi:10.1002/(sici)1096-911x(199704)28:4<294::aid-mpo9>3.0.co;2-d
19. Lautz TB, Xue W, Luo LY, et al. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer . Jul 2023;70(7):e30357. doi:10.1002/pbc.30357
20. Rogers T, Zanetti I, Coppadoro B, et al. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies. Pediatr Blood Cancer . Sep 2022;69(9):e29739. doi:10.1002/pbc.29739
21. Winter S, Fasola S, Brisse H, Mosseri V, Orbach D. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy. Pediatr Blood Cancer . Nov 2015;62(11):1935-41. doi:10.1002/pbc.25622
22. Guerin F, Rogers T, Minard-Colin V, et al. Outcome of localized liver-bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG)-RMS 2005 study. Pediatr Blood Cancer . Jul 2019;66(7):e27725. doi:10.1002/pbc.27725
23. Terwisscha van Scheltinga SEJ, Wijnen M, Martelli H, et al. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study. Cancer Med . Oct 2020;9(20):7580-7589. doi:10.1002/cam4.3365
24. Wolden SL, Lyden ER, Arndt CA, et al. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children’s Oncology Group. Int J Radiat Oncol Biol Phys . Dec 1 2015;93(5):1071-6. doi:10.1016/j.ijrobp.2015.08.040
25. Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children’s oncology group. J Pediatr Surg . Nov 2010;45(11):2160-8. doi:10.1016/j.jpedsurg.2010.07.021
26. Lautz TB, Chi YY, Li M, et al. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children’s Oncology Group.Cancer . Jan 15 2021;127(2):275-283. doi:10.1002/cncr.33275
27. Bradley JA, Kayton ML, Chi YY, et al. Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children’s Oncology Group.Int J Radiat Oncol Biol Phys . Jan 1 2019;103(1):19-27. doi:10.1016/j.ijrobp.2018.08.017
28. Cecchetto G, Carli M, Sotti G, et al. Importance of local treatment in pediatric soft tissue sarcomas with microscopic residual after primary surgery: results of the Italian Cooperative Study RMS-88.Med Pediatr Oncol . Feb 2000;34(2):97-101. doi:10.1002/(sici)1096-911x(200002)34:2<97::aid-mpo4>3.0.co;2-8
29. Dall’Igna P, Bisogno G, Ferrari A, et al. Primary transcrotal excision for paratesticular rhabdomyosarcoma: is hemiscrotectomy really mandatory? Cancer . Apr 15 2003;97(8):1981-4. doi:10.1002/cncr.11284
30. Hays DM, Lawrence W, Jr., Wharam M, et al. Primary reexcision for patients with ’microscopic residual’ tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg . Jan 1989;24(1):5-10. doi:10.1016/s0022-3468(89)80290-8
31. Bisogno G, Jenney M, Bergeron C, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.Lancet Oncol . Aug 2018;19(8):1061-1071. doi:10.1016/S1470-2045(18)30337-1
32. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer . Jan 15 1988;61(2):209-20. doi:10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l
33. Koscielniak E, Herbst M, Niethammer D, Treuner J. [Improved local tumor control by early and risk-adjusted use of radiotherapy in primary non-resectable rhabdomyosarcomas: results of CWS 81 and 86 studies].Klin Padiatr . Jul-Aug 1994;206(4):269-76. Verbesserung der lokalen Tumorkontrolle durch einen fruhen und risikoadaptierten Einsatz der Radiotherapie bei primar nicht resektablen Rhabdomyosarkomen: Ergebnisse der CWS 81 und 86 Studien. doi:10.1055/s-2008-1046613
34. Sparber-Sauer M, Dietzschold M, Schonstein A, et al. Radiotherapy and long-term sequelae in pediatric patients with parameningeal rhabdomyosarcoma: Results of two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatr Blood Cancer . Jan 2024;71(1):e30742. doi:10.1002/pbc.30742
35. Wharam M, Beltangady M, Hays D, et al. Localized orbital rhabdomyosarcoma. An interim report of the Intergroup Rhabdomyosarcoma Study Committee. Ophthalmology . Mar 1987;94(3):251-4.
36. Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment–results of an international workshop. J Clin Oncol . Jan 1 2001;19(1):197-204. doi:10.1200/JCO.2001.19.1.197
37. Minard-Colin V, Walterhouse D, Bisogno G, et al. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups. Pediatr Blood Cancer . Sep 2018;65(9):e27096. doi:10.1002/pbc.27096
38. Lawrence W, Jr., Hays DM, Heyn R, Beltangady M, Maurer HM. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg . Oct 1988;12(5):676-84. doi:10.1007/BF01655884
39. Lawrence W, Jr., Neifeld JP. Soft tissue sarcomas. Curr Probl Surg . Nov 1989;26(11):753-827. doi:10.1016/0011-3840(89)90036-1
40. Blakely ML, Andrassy RJ, Raney RB, et al. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. J Pediatr Surg . Mar 2003;38(3):347-53. doi:10.1053/jpsu.2003.50106
41. Andrassy RJ, Wiener ES, Raney RB, et al. Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg . May 1999;34(5):731-4; discussion 734-5. doi:10.1016/s0022-3468(99)90365-2
42. Flamant F, Rodary C, Voute PA, Otten J. Primary chemotherapy in the treatment of rhabdomyosarcoma in children: trial of the International Society of Pediatric Oncology (SIOP) preliminary results.Radiother Oncol . Apr 1985;3(3):227-36. doi:10.1016/s0167-8140(85)80031-1
43. Heyn R, Newton WA, Raney RB, et al. Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol . Jan 1997;15(1):69-75. doi:10.1200/JCO.1997.15.1.69
44. Lautz TB, Chi YY, Tian J, et al. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children’s Oncology Group. Int J Cancer . Sep 1 2020;147(5):1419-1426. doi:10.1002/ijc.32896
45. Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol . Aug 1 2009;27(22):3705-11. doi:10.1200/JCO.2008.19.5933
46. Hays DM, Raney RB, Crist WM, et al. Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg . Oct 1990;25(10):1100-5. doi:10.1016/0022-3468(90)90228-2
47. Regine WF, Fontanesi J, Kumar P, et al. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. Int J Radiat Oncol Biol Phys . Feb 1 1995;31(3):485-91. doi:10.1016/0360-3016(94)00352-L
48. Rodeberg DA, Wharam MD, Lyden ER, et al. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer . Jul 1 2015;137(1):204-11. doi:10.1002/ijc.29351
49. Mohan AC, Venkatramani R, Okcu MF, et al. Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer . Feb 2018;65(2)doi:10.1002/pbc.26859
50. Ben Arush M, Minard-Colin V, Mosseri V, et al. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer . Jan 2015;51(2):193-201. doi:10.1016/j.ejca.2014.11.009
51. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol . Nov 1999;17(11):3487-93. doi:10.1200/JCO.1999.17.11.3487
52. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol . Apr 1 2011;29(10):1319-25. doi:10.1200/JCO.2010.32.1984
53. Sparber-Sauer M, Stegmaier S, Vokuhl C, et al. Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer . Jun 2019;66(6):e27652. doi:10.1002/pbc.27652
54. Heinz AT, Ebinger M, Schonstein A, et al. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). Pediatr Blood Cancer . Jul 2023;70(7):e30363. doi:10.1002/pbc.30363
55. Bergamaschi L, Chiaravalli S, Livellara V, et al. Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.Pediatr Blood Cancer . Jan 2023;70(1):e30050. doi:10.1002/pbc.30050
56. Hayes-Jordan A, Doherty DK, West SD, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg . Apr 2006;41(4):633-8; discussion 633-8. doi:10.1016/j.jpedsurg.2005.12.002
57. De Corti F, Bisogno G, Dall’Igna P, et al. Does surgery have a role in the treatment of local relapses of non-metastatic rhabdomyosarcoma?Pediatr Blood Cancer . Dec 15 2011;57(7):1261-5. doi:10.1002/pbc.23225
58. Dantonello TM, Int-Veen C, Schuck A, et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma.Pediatr Blood Cancer . Aug 2013;60(8):1267-73. doi:10.1002/pbc.24488
59. Fetzko S, Fonseca A, Frances Wedekind M, et al. Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? J Pediatr Hematol Oncol . Aug 1 2022;44(6):305-312. doi:10.1097/MPH.0000000000002429
60. Raney B, Huh W, Hawkins D, et al. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children’s Oncology Group. Pediatr Blood Cancer . Mar 2013;60(3):371-6. doi:10.1002/pbc.24289
61. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer . Jul 1 2005;104(1):183-90. doi:10.1002/cncr.21138
62. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol . Jan 20 2008;26(3):406-13. doi:10.1200/JCO.2007.12.2382
63. Mattke AC, Bailey EJ, Schuck A, et al. Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas? Pediatr Blood Cancer . Jul 2009;52(7):772-6. doi:10.1002/pbc.21906
64. Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg . May 1999;34(5):736-41; discussion 741-2. doi:10.1016/s0022-3468(99)90366-4
65. Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies.Cancer . Dec 1 2007;110(11):2561-7. doi:10.1002/cncr.23079
66. Spunt SL, Lobe TE, Pappo AS, et al. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg . Feb 2000;35(2):309-16. doi:10.1016/s0022-3468(00)90030-7
Table S1: The priority questions guiding the evidence review and synthesis for the guidelines.